Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Osteosarcoma 29Dendritic Cell Sarcoma, Interdigitating 25Lymphoma 20Burkitt Lymphoma 20Lymphoma, Large B-Cell, Diffuse 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma, Non-Hodgkin 16Leukemia 16Lymphoma, Large-Cell, Immunoblastic 15Lymphoma, Follicular 14Sarcoma 13Recurrence 13Multiple Myeloma 13Leukemia, Myeloid, Acute 13Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Mantle-Cell 12Lymphoma, B-Cell, Marginal Zone 12Hodgkin Disease 12Neoplasms, Plasma Cell 11Myelodysplastic Syndromes 11Leukemia, Myeloid, Accelerated Phase 11Myeloproliferative Disorders 10Leukemia, Myelomonocytic, Chronic 10Congenital Abnormalities 10Leukemia, Myelomonocytic, Juvenile 9Leukemia, Myeloid, Chronic-Phase 9Blast Crisis 9Sezary Syndrome 8Primary Myelofibrosis 8Mycosis Fungoides 8

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Adenocarcinoma × Methotrexate × Sarcoma × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡